Effect of Transarterial Chemoembolization on Health-Related Quality of Life in Patients With Hepatocellular Carcinoma
Authors:
- Prasanth Thayyil SudheendranPSPrasanth Thayyil Sudheendran
- Prasanth T SPSPrasanth T S
- Shabnam SSSShabnam S
Open Access
- 18 April 2025
- journal article
- Published by Springer Nature in Cureus
- Vol. 17 (4)
Abstract
Background and aim: We evaluated health-related quality of life (HRQoL) in patients with hepatocellular carcinoma (HCC) before and after transarterial chemoembolization (TACE) and the clinical and biochemical factors that can predict changes in quality of life (QoL). Methods: A total of 45 patients were enrolled in the study and followed up for a period of three months. HRQoL was assessed using an HCC-specific questionnaire at baseline, two weeks, and three months. Tumor response was evaluated at six weeks using the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. Results: Before TACE, the aspects of the functional scales most significantly impacted were global health status (53.1±29.3%) and physical functioning (68.7±20.7%). The commonly reported symptoms and their corresponding QoL scores were as follows: fatigue (46.4±32.5%), followed by insomnia (32.6±36.6%) and abdominal pain (32.2±30.8%). Financial constraints (63.0±37.1%) were also a significant concern for the patients. Most functional and symptom scores showed a reduction at two weeks and improvement at three months. Global health status improved to 68±28.2% (p=0.455), whereas physical functioning improved to 73.8±23.2% (p=0.005) at three months following TACE. After three months following TACE, the QoL scores for the following symptoms improved from baseline: fatigue (30.5±28.2; p=0.012), insomnia (25.9±27.4; p=0.896), and pain (28.5±30.8; p=0.005). High alpha-fetoprotein (AFP), high C-reactive protein (CRP), low albumin, and an increase in Model for End-stage Liver Disease (MELD) and Child-Turcotte-Pugh (CTP) scores were found to have a negative impact at three months. Following TACE, 26 (57%), nine (20%), three (7%), and seven (16%) patients had complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD), respectively. Quality of life scores showed a positive response at three months in subjects with CR, PR, and SD, while in those with PD, QoL continued to deteriorate over time. Conclusion: Effective symptom management, along with the implementation of coping strategies to improve functionality, is crucial when caring for patients who have undergone TACE, particularly during the first two weeks post-procedure.Keywords
This publication has 15 references indexed in Scilit:
- BCLC strategy for prognosis prediction and treatment recommendation: The 2022 updateJournal of Hepatology, 2021
- LI‐RADS: Review and updatesClinical Liver Disease, 2021
- Quality of life in patients undergoing repetitive TACE for the treatment of intermediate stage HCCJournal of Cancer Research and Clinical Oncology, 2018
- Health-Related Quality of Life in Patients with Hepatocellular Carcinoma Treated with Initial Transarterial ChemoembolizationCardioVascular and Interventional Radiology, 2017
- Epidemiology of Hepatocellular Carcinoma in IndiaJournal of Clinical and Experimental Hepatology, 2014
- Longitudinal Quality of Life Assessment of Patients with Hepatocellular Carcinoma after Primary Transarterial ChemoembolizationJournal of Vascular and Interventional Radiology, 2010
- Quality of life after radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison with transcatheter arterial chemoembolization aloneQuality of Life Research, 2006
- Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18European Journal of Cancer, 2004
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaHepatology, 2002
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993